Has Marc Sandberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $566,757 in general payments to Marc Sandberg, MD across 1,603 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marc Sandberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marc Sandberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marc Sandberg, MD

Endocrinology, Diabetes & Metabolism · Flemington, NJNPI 1770557837

Payments from drug & device makers

$566,757in general payments, 2019–2025

Across 1,603 payments — averaging $353.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$187K
Sanofi-aventis U.S. LLC$149K
Novo Nordisk$111K
Boehringer Ingelheim$27K
Valeritas, Inc.$25K
Corcept Therapeutics$16K
plus $53K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	377	$186,922
Sanofi-aventis U.S. LLC	172	$148,820
Novo Nordisk	235	$110,905
Boehringer Ingelheim	83	$26,995
Valeritas, Inc.	31	$24,823
Corcept Therapeutics	91	$15,550
AstraZeneca(2 entities)	48	$10,417
Intuity Medical Inc	23	$10,320
AbbVie	33	$8,079
Johnson & Johnson	20	$6,297
Zealand Pharma US, Inc.	8	$3,862
Amneal Pharmaceuticals LLC	40	$3,329
Recordati_rare_diseases_inc.	21	$2,302
Mannkind Corporation	45	$1,510
Amgen(2 entities)	42	$637
Antares Pharma, Inc.	27	$478
Dexcom, Inc.	22	$451
Medtronic(2 entities)	19	$387
Pfizer	23	$365
Abbott	17	$343
Insulet Corporation	20	$342
Bayer	16	$300
Radius Health, Inc.	15	$292
Tandem Diabetes Care, Inc.	11	$268
Xeris Pharmaceuticals, Inc.	17	$249
Amarin Pharma, Inc.	14	$201
Astellas Pharma US Inc	6	$175
Merck	10	$132
Embecta Corp.	2	$120
Tolmar, Inc.	7	$114
Cequr Corporation	4	$113
IBSA Pharma Inc.	8	$110
Acella Pharmaceuticals, LLC	6	$108
Currax Pharmaceuticals LLC	7	$103
Novartis	5	$87
Senseonics, Incorporated	6	$75
Lifescan, Inc.	5	$74
Kowa Pharmaceuticals America, Inc.	5	$67
Madrigal Pharmaceuticals	3	$61
Esperion Therapeutics, Inc.	4	$59
Clarus Therapeutics Inc.	4	$58
Ascendis Pharma Endocrinology Inc	3	$52
Neurocrine Biosciences, Inc.	3	$52
Kyowa Kirin, Inc.	3	$50
Companion Medical, Inc.	3	$47
Ultragenyx Pharmaceutical Inc.	3	$47
Amryt Pharma Holdings Ltd	3	$45
Eisai Inc.	3	$45
Shire North American Group Inc	3	$43
BD	3	$43
Strongbridge US Inc.	1	$41
Soleno Therapeutics, Inc.	2	$34
Vivus LLC	2	$30
Azurity Pharmaceuticals, Inc.	2	$30
Regeneron Healthcare Solutions, Inc.	2	$29
Topcon Healthcare Solutions, Inc.	1	$27
BETA Bionics, Inc.	1	$25
Verity Pharmaceuticals Inc.	1	$24
Aytu Biopharma, Inc.	2	$24
Halozyme Inc	1	$22

How this compares

$566,757 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$146,490

Medicare patients

472

Services billed

2,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Flemington

Robert LindFlemington$32K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K
Sunil AsnaniBrick$295K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →